August 23, 2023
Alterome Therapeutics, Inc., a frontrunner in precision oncology, has announced the addition of Dr. Andrew S. Chi, M.D., Ph.D., to its executive team as Chief Medical Officer. The move marks an essential step for the biotech firm, which is gearing up to initiate clinical trials for its two key programs next year.
Dr. Chi, with an illustrious career spanning over two decades in oncology research and drug development, is poised to be a significant asset to Alterome’s mission. Eric Murphy, Ph.D., the CEO and CSO of Alterome Therapeutics, shared his optimism, noting, “Andrew’s comprehensive expertise in oncology, ranging from clinical and translational research to global Phase III studies, fortifies our leadership as we steer Alterome’s next-gen precision oncology projects.”
The new Chief Medical Officer expressed his enthusiasm for the venture, stating, “I’m eager to be part of Alterome’s vision in innovating alteration-specific therapies. The prospect of collaborating with a proficient team of oncology experts and driving the company’s primary two programs into clinical phases next year is truly invigorating.”
Before joining Alterome, Dr. Chi held pivotal roles at top-tier biotech firms. He served as the Vice President of Clinical Development at Bright Peak Therapeutics and was instrumental as the Executive Medical Director at Mirati Therapeutics. There, he championed the clinical development of adagrasib, leading the drug to receive the FDA’s Breakthrough Therapy designation in the treatment of lung cancer. His journey also includes significant tenure at Neon Therapeutics, culminating in its acquisition by BioNTech.
However, Dr. Chi’s accomplishments aren’t limited to the biotech industry. In academia, he held the title of Chief of Neuro-oncology and was the Co-Director of the Brain Tumor Center at New York University. Additionally, his role as the founder and director of the Translational Neuro-Oncology Laboratory at Massachusetts General Hospital cemented his reputation in the field. He has over 90 peer-reviewed publications to his name and has been a Senior Editor for Clinical Cancer Research since 2017.
Alterome Therapeutics is uniquely positioned in the biotech sector, focusing on the development of alteration-specific therapeutics targeting validated oncogenic drivers. With a robust team with an established track record in precision oncology, the addition of Dr. Chi further accentuates the company’s commitment to making strides in the fight against cancer.
